132 related articles for article (PubMed ID: 14627979)
1. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Akiyama M; Mitsiades N; Mitsiades C; Podar K; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2003 Nov; 22(52):8386-93. PubMed ID: 14627979
[TBL] [Abstract][Full Text] [Related]
2. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
[TBL] [Abstract][Full Text] [Related]
3. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver.
Graf D; Kohlmann C; Haselow K; Gehrmann T; Bode JG; Häussinger D
Hepatology; 2006 Nov; 44(5):1206-17. PubMed ID: 17058237
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
5. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells.
Ogata A; Chauhan D; Urashima M; Teoh G; Treon SP; Anderson KC
Clin Cancer Res; 1997 Jun; 3(6):1017-22. PubMed ID: 9815779
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
9. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
[TBL] [Abstract][Full Text] [Related]
11. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
12. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Hideshima T; Podar K; Chauhan D; Ishitsuka K; Mitsiades C; Tai YT; Hamasaki M; Raje N; Hideshima H; Schreiner G; Nguyen AN; Navas T; Munshi NC; Richardson PG; Higgins LS; Anderson KC
Oncogene; 2004 Nov; 23(54):8766-76. PubMed ID: 15480425
[TBL] [Abstract][Full Text] [Related]
13. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
[TBL] [Abstract][Full Text] [Related]
14. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
15. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway.
Sagawa M; Nakazato T; Uchida H; Ikeda Y; Kizaki M
Cancer Sci; 2008 Sep; 99(9):1820-6. PubMed ID: 18544087
[TBL] [Abstract][Full Text] [Related]
16. IL-6 signal transduction and its physiological roles: the signal orchestration model.
Kamimura D; Ishihara K; Hirano T
Rev Physiol Biochem Pharmacol; 2003; 149():1-38. PubMed ID: 12687404
[TBL] [Abstract][Full Text] [Related]
17. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Godoy-Tundidor S; Cavarretta IT; Fuchs D; Fiechtl M; Steiner H; Friedbichler K; Bartsch G; Hobisch A; Culig Z
Prostate; 2005 Jul; 64(2):209-16. PubMed ID: 15712220
[TBL] [Abstract][Full Text] [Related]
19. Differential stimulation-induced receptor localization in lipid rafts for interleukin-6 family cytokines signaling through the gp130/leukemia inhibitory factor receptor complex.
Port MD; Gibson RM; Nathanson NM
J Neurochem; 2007 May; 101(3):782-93. PubMed ID: 17448148
[TBL] [Abstract][Full Text] [Related]
20. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
